Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season?
by Zacks Equity Research
Clovis Oncology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
AstraZeneca's Lynparza Label Now Includes Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
Clovis Up More Than 50% in 2017: What's Driving the Stock?
by Zacks Equity Research
Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
by Zacks Equity Research
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU
by Zacks Equity Research
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
What to Expect from Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.
Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
by Zacks Equity Research
AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.
Will Endocyte (ECYT) Disappoint This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
Is Aerie (AERI) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.
What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
by Zacks Equity Research
Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
by Zacks Equity Research
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
What's in the Offing for Intercept (ICPT) in Q3 Earnings?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.